Semaglutide Patent Expiration
Semaglutide is used for treating Type 2 diabetes as an adjunct to diet and exercise to improve glycemic control in adults. It was first introduced by Novo Nordisk Inc
Semaglutide Patents
Given below is the list of patents protecting Semaglutide, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Wegovy | US11318191 | GLP-1 compositions and uses thereof | Feb 17, 2041 | Novo |
| Wegovy | US12029779 | Semaglutide in medical therapy | Oct 10, 2038 | Novo |
| Wegovy | US10888605 | GLP-1 compositions and uses thereof | Aug 24, 2038 | Novo |
| Wegovy | US11752198 | GLP-1 compositions and uses thereof | Aug 24, 2038 | Novo |
| Rybelsus | US10278923 | Oral dosing of GLP-1 compounds | May 02, 2034 | Novo |
| Ozempic | US10335462 | Use of long-acting GLP-1 peptides | Jun 21, 2033 | Novo |
| Wegovy | US9764003 | Use of long-acting GLP-1 peptides | Jun 21, 2033 | Novo |
| Rybelsus | US10933120 | Compositions of GLP-1 peptides and preparation thereof | Mar 15, 2033 | Novo |
| Rybelsus | US11759501 | Compositions of GLP-1 peptides and preparation thereof | Mar 15, 2033 | Novo |
| Rybelsus | US11759502 | Compositions of GLP-1 peptides and preparation thereof | Mar 15, 2033 | Novo |
| Rybelsus | US11759503 | Compositions of GLP-1 peptides and preparation thereof | Mar 15, 2033 | Novo |
| Ozempic | US9132239 | Dial-down mechanism for wind-up pen | Feb 01, 2032 | Novo |
| Rybelsus | US10086047 | Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid | Dec 16, 2031 | Novo |
| Rybelsus | US10960052 | Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl) amino) caprylic acid | Dec 16, 2031 | Novo |
| Rybelsus | US11382957 | Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid | Dec 16, 2031 | Novo |
| Rybelsus | US9278123 | Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid | Dec 16, 2031 | Novo |
| Ozempic | US8129343 | Acylated GLP-1 compounds | Dec 05, 2031 | Novo |
| Rybelsus | US8129343 | Acylated GLP-1 compounds | Dec 05, 2031 | Novo |
| Wegovy | US8129343 | Acylated GLP-1 compounds | Dec 05, 2031 | Novo |
| Ozempic | US9457154 | Injection device with an end of dose feedback mechanism | Sep 29, 2027 | Novo |
| Ozempic | US9457154 | Injection device with an end of dose feedback mechanism | Sep 27, 2027 | Novo |
| Ozempic | US9687611 | Injection device with torsion spring and rotatable display | Feb 27, 2027 | Novo |
| Ozempic | USRE46363 | Dial-down mechanism for wind-up pen | Aug 03, 2026 | Novo |
| Ozempic | US10220155 | Syringe device with a dose limiting mechanism and an additional safety mechanism | Jul 17, 2026 | Novo |
| Ozempic | US11097063 | Syringe device with a dose limiting mechanism and an additional safety mechanism | Jul 17, 2026 | Novo |
| Ozempic | US8920383 | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left | Jul 17, 2026 | Novo |
| Ozempic | US9775953 | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left | Jul 17, 2026 | Novo |
| Ozempic | US8536122 | Acylated GLP-1 compounds | Mar 20, 2026 | Novo |
| Rybelsus | US8536122 | Acylated GLP-1 compounds | Mar 20, 2026 | Novo |
| Wegovy | US8536122 | Acylated GLP-1 compounds | Mar 20, 2026 | Novo |
| Ozempic | US10357616 | Injection device with an end of dose feedback mechanism | Jan 20, 2026 | Novo |
| Ozempic | US10376652 | Automatic injection device with a top release mechanism | Jan 20, 2026 | Novo |
| Ozempic | US11311679 | Automatic injection device with a top release mechanism | Jan 20, 2026 | Novo |
| Ozempic | US9108002 | Automatic injection device with a top release mechanism | Jan 20, 2026 | Novo |
| Ozempic | US9616180 | Automatic injection device with a top release mechanism | Jan 20, 2026 | Novo |
| Ozempic | US9861757 | Injection device with an end of dose feedback mechanism | Jan 20, 2026 | Novo |
| Ozempic | US11446443 | Injection device with torsion spring and rotatable display | Oct 20, 2025 | Novo |
| Ozempic | US8684969 | Injection device with torsion spring and rotatable display | Oct 20, 2025 | Novo |
| Ozempic | US8114833 | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices | Aug 13, 2025 | Novo |
| Ozempic | US7762994 | Needle mounting system and a method for mounting a needle assembly |
May 23, 2024
(Expired) | Novo |
| Ozempic | US8579869 | Needle mounting system and a method for mounting a needle assembly |
Jun 30, 2023
(Expired) | Novo |
| Ozempic | US6899699 | Automatic injection device with reset feature |
Jan 02, 2022
(Expired) | Novo |
| Ozempic | US8672898 | Automatic injection device with reset feature |
Jan 02, 2022
(Expired) | Novo |
| Ozempic | US9486588 | Automatic injection device with reset feature |
Jan 02, 2022
(Expired) | Novo |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Semaglutide's patents.
Latest Legal Activities on Semaglutide's Patents
Given below is the list recent legal activities going on the following patents of Semaglutide.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 20 Jun, 2024 | US10888605(Litigated) |
| Email Notification Critical | 20 Sep, 2023 | US11759501 |
| Email Notification Critical | 20 Sep, 2023 | US11759503 |
| Email Notification Critical | 20 Sep, 2023 | US11759502 |
| Mail Patent eGrant Notification | 19 Sep, 2023 | US11759502 |
| Mail Patent eGrant Notification | 19 Sep, 2023 | US11759501 |
| Sequence Moved to Public Database | 19 Sep, 2023 | US11759501 |
| Patent Issue Date Used in PTA Calculation Critical | 19 Sep, 2023 | US11759501 |
| Recordation of Patent Grant Mailed Critical | 19 Sep, 2023 | US11759501 |
| Patent eGrant Notification | 19 Sep, 2023 | US11759501 |
Semaglutide's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Semaglutide:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry. Semaglutide has 5 clinical trials that have been verified in 2024. Out of these 5, 1 trial is in PHASE4.